U.S. Drug Utilization Management MarketU.S. Drug Utilization Management Market By Type (Prospective Review (pDUR), Concurrent Review (cDUR) and Retrospective Review (rDUR)), By Program Type (In-house and Outsourced), By End-use (PBMs, Health Plan Provider/Payors and Pharmacies), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2026-2035

Published date: March 2026
Report ID: 180187
Number of Pages: 275
Format:

Fact Checked

Cite this Research

Table of Content
- 1. Research Methodology and Data Source
  - 1.1. Methodology/Research Approach
  - 1.2. Market Size Estimation
  - 1.3. Market Breakdown and Data Triangulation
  - 1.4. Data Sources
  - 1.5. Secondary Sources
  - 1.6. Primary Sources
- 2. Executive Summary
  - 2.1. Taxonomy
  - 2.2. Market Outlook
  - 2.3. Key Facts and Figures
  - 2.4. Major Players in U.S. drug utilization management Market
- 3. Market Overview
  - 3.1. Industry Overview
  - 3.2. Segmental Overview
  - 3.3. Market Dynamics
  - 3.3.1. Drivers
  - 3.3.2. Restraints
  - 3.3.3. Opportunities
  - 3.3.4. Trends
  - 3.4. Regulatory Framework
  - 3.5. Opportunity Map Analysis
  - 3.6. Opportunity Orbits
  - 3.7. Market Investment Feasibility Index
  - 3.8. PESTLE Analysis
  - 3.9. PORTER’S Five Force Analysis
  - 3.10. Drivers & Restraints Impact Analysis
  - 3.11. Patient Journey Mapping
  - 3.12. Technological Landscape
  - 3.13. Product Life Cycle Analysis
  - 3.14. Value Chain Analysis
  - 3.14.1. List of Raw Material Suppliers
  - 3.14.2. List of U.S. drug utilization management Manufacturers
  - 3.14.3. List of Dealer/Distributors
  - 3.14.4. List of Potential Customers
  - 3.15. Cost Structure Analysis
- 4. Macro-economic Factors
- 5. Impact of Current Geopolitical Scenario
- 6. U.S. drug utilization management Market Analysis and Forecast, By Type
  - 6.1. Key Findings
  - 6.2. U.S. drug utilization management Market Size Value (US$ Mn) Forecast, By Type, 2020-2035
  - 6.2.1. Prospective Review
  - 6.2.2. Concurrent Review
  - 6.2.3. Retrospective Review
  - 6.3. U.S. drug utilization management Market Attractiveness Analysis, By Type
- 7. U.S. drug utilization management Market Analysis and Forecast, By Program Type
  - 7.1. Key Findings
  - 7.2. U.S. drug utilization management Market Size Value (US$ Mn) Forecast, By Program Type, 2020-2035
  - 7.2.1. In-House
  - 7.2.2. Outsourced
  - 7.3. U.S. drug utilization management Market Attractiveness Analysis, By Program Type
  - 8. U.S. drug utilization management Market Analysis and Forecast, By End-Use
  - 8.1. Key Findings
  - 8.2. U.S. drug utilization management Market Size Value (US$ Mn) Forecast, By End-Use, 2020-2035
  - 8.2.1. PBMs
  - 8.2.2. Health Plan Provider/Payors
  - 8.2.3. Pharmacies
  - 8.3. U.S. drug utilization management Market Attractiveness Analysis, By End-Use
- 9. Competitive Landscape & Company Profiles
  - 9.1. Market Competition Scenario Analysis, By Company
  - 9.2. Competitor Landscape
  - 9.3. Company Share Analysis
  - 9.4. Company Profiles
    
    9.4.1. Prime Therapeutics LLC
    
    9.4.1.1. Company Details
    
    9.4.1.2. Business Overview
    
    9.4.1.3. Product Portfolio
    
    9.4.1.4. Financial Insights
    
    9.4.1.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.1.6. SWOT Analysis
    
    9.4.1.7. Geographic Footprint
    
    9.4.2. MedicusRx
    
    9.4.2.1. Company Details
    
    9.4.2.2. Business Overview
    
    9.4.2.3. Product Portfolio
    
    9.4.2.4. Financial Insights
    
    9.4.2.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.2.6. SWOT Analysis
    
    9.4.2.7. Geographic Footprint
    
    9.4.3. EmblemHealth
    
    9.4.3.1. Company Details
    
    9.4.3.2. Business Overview
    
    9.4.3.3. Product Portfolio
    
    9.4.3.4. Financial Insights
    
    9.4.3.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.3.6. SWOT Analysis
    
    9.4.3.7. Geographic Footprint
    
    9.4.4. Optum, Inc
    
    9.4.4.1. Company Details
    
    9.4.4.2. Business Overview
    
    9.4.4.3. Product Portfolio
    
    9.4.4.4. Financial Insights
    
    9.4.4.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.4.6. SWOT Analysis
    
    9.4.4.7. Geographic Footprint
    
    9.4.5. Point32Health, Inc
    
    9.4.5.1. Company Details
    
    9.4.5.2. Business Overview
    
    9.4.5.3. Product Portfolio
    
    9.4.5.4. Financial Insights
    
    9.4.5.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.5.6. SWOT Analysis
    
    9.4.5.7. Geographic Footprint
    
    9.4.6. AssureCare LLC
    
    9.4.6.1. Company Details
    
    9.4.6.2. Business Overview
    
    9.4.6.3. Product Portfolio
    
    9.4.6.4. Financial Insights
    
    9.4.6.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.6.6. SWOT Analysis
    
    9.4.6.7. Geographic Footprint
    
    9.4.7. MindRx Group
    
    9.4.7.1. Company Details
    
    9.4.7.2. Business Overview
    
    9.4.7.3. Product Portfolio
    
    9.4.7.4. Financial Insights
    
    9.4.7.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.7.6. SWOT Analysis
    
    9.4.7.7. Geographic Footprint
    
    9.4.8. Agadia Systems, Inc
    
    9.4.8.1. Company Details
    
    9.4.8.2. Business Overview
    
    9.4.8.3. Product Portfolio
    
    9.4.8.4. Financial Insights
    
    9.4.8.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.8.6. SWOT Analysis
    
    9.4.8.7. Geographic Footprint
    
    9.4.9. Elevance Health (CarelonRx)
    
    9.4.9.1. Company Details
    
    9.4.9.2. Business Overview
    
    9.4.9.3. Product Portfolio
    
    9.4.9.4. Financial Insights
    
    9.4.9.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.9.6. SWOT Analysis
    
    9.4.9.7. Geographic Footprint
    
    9.4.10. ExlService Holdings, Inc.
    
    9.4.10.1. Company Details
    
    9.4.10.2. Business Overview
    
    9.4.10.3. Product Portfolio
    
    9.4.10.4. Financial Insights
    
    9.4.10.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.10.6. SWOT Analysis
    
    9.4.10.7. Geographic Footprint
    
    9.4.11. MRIoA
    
    9.4.11.1. Company Details
    
    9.4.11.2. Business Overview
    
    9.4.11.3. Product Portfolio
    
    9.4.11.4. Financial Insights
    
    9.4.11.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.11.6. SWOT Analysis
    
    9.4.11.7. Geographic Footprint
    
    9.4.12. S&C Technologies, Inc.
    
    9.4.12.1. Company Details
    
    9.4.12.2. Business Overview
    
    9.4.12.3. Product Portfolio
    
    9.4.12.4. Financial Insights
    
    9.4.12.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.12.6. SWOT Analysis
    
    9.4.12.7. Geographic Footprint
    
    9.4.13. In-House Providers
    
    9.4.13.1. Company Details
    
    9.4.13.2. Business Overview
    
    9.4.13.3. Product Portfolio
    
    9.4.13.4. Financial Insights
    
    9.4.13.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.13.6. SWOT Analysis
    
    9.4.13.7. Geographic Footprint
    
    9.4.14. Ultimate Health Plans
    
    9.4.14.1. Company Details
    
    9.4.14.2. Business Overview
    
    9.4.14.3. Product Portfolio
    
    9.4.14.4. Financial Insights
    
    9.4.14.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.14.6. SWOT Analysis
    
    9.4.14.7. Geographic Footprint
List of Tables
- Table 1: U.S. drug utilization management Market Value (US$ Mn), By Type, 2020-2035
- Table 2: U.S. drug utilization management Market Value (US$ Mn), By Program Type, 2020-2035
- Table 3: U.S. drug utilization management Market Value (US$ Mn), By End-Use, 2020-2035
List of Figures
- Figure 1: U.S. drug utilization management Market Value (US$ Mn), 2020-2035
- Figure 2: U.S. drug utilization management Market Value Share (%) Analysis, By Type, 2025 & 2035
- Figure 3: U.S. drug utilization management Market Value Share (%) Analysis, By Program Type, 2025 & 2035
- Figure 4: U.S. drug utilization management Market Value Share (%) Analysis, By End-Use, 2025 & 2035
- Figure 5: U.S. drug utilization management Market Value Share (%) Analysis, By Type, 2020, 2025 and 2035
- Figure 6: U.S. drug utilization management Market Attractiveness Analysis, By Type
- Figure 7: U.S. drug utilization management Market Value Share (%) Analysis, By Program Type, 2020, 2025 and 2035
- Figure 8: U.S. drug utilization management Market Attractiveness Analysis, By Program Type
- Figure 9: U.S. drug utilization management Market Value Share (%) Analysis, By End-Use, 2020, 2025 and 2035
- Figure 10: U.S. drug utilization management Market Attractiveness Analysis, By End-Use
- Prime Therapeutics LLC
- MedicusRx
- EmblemHealth
- Optum, Inc.
- Point32Health, Inc.
- AssureCare LLC
- MindRx Group
- Agadia Systems, Inc
- Elevance Health (CarelonRx)
- ExlService Holdings, Inc.
- MRIoA
- S&C Technologies, Inc.
- In-House Providers
- Ultimate Health Plans